News
EQS-News: Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q3 2023 Earnings CallNov 01, 2023, 5:00 p.m. ET
Operator
Source Fool.com
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q3 2023 Earnings CallNov 01, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q3 2023 Earnings CallNov 01, 2023, 8:00 a.m. ET
Operator
Source Fool.com
2 Incredibly Cheap Dividend Stocks to Buy Hand Over Fist Ahead of 2024
Dividend stocks often deliver market-beating returns over long periods of time. However, their quarterly distribution isn't the core reason underlying this trend. Rather, the real driver is their
Pfizer Posted a Steep Loss. Is It Time to Sell?
It's been about a couple of weeks since Pfizer (NYSE: PFE) promised to make Halloween extra spooky by warning us that third-quarter results would be disappointing.
It turns out the warning was more
EQS-News: Evotec SE to announce results for the first nine months 2023 on 08 November 2023
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and
Why Ardelyx Stock Soared Today
Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results.
Ardelyx's quarterly revenue skyrocketed to $56.4
Pfizer (PFE) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Pfizer (NYSE: PFE)Q3 2023 Earnings CallOct 31, 2023, 10:00 a.m. ET
Operator
Source Fool.com
Why Sarepta Therapeutics Stock Is Crashing Today
Shares of Sarepta Therapeutics (NASDAQ: SRPT) were crashing 43.6% lower as of 11:10 a.m. ET on Tuesday. The huge sell-off came after the company announced top-line results from its phase 3 Embark
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a
Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors
On Oct. 13, regulators at the Food and Drug Administration (FDA) ruled that Pfizer's (NYSE: PFE) new drug for moderate to severe ulcerative colitis (UC), Velsipity, was ready for prime time. That
Is AbbVie Still a Good Dividend Stock to Buy?
One thing income seekers don't want to see from the businesses they invest in is a major disruption to their incoming cash flows. Unfortunately for shareholders of AbbVie (NYSE: ABBV), the
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent
Why AbbVie Stock Was a Winner on Monday
Pharmaceutical company AbbVie (NYSE: ABBV) was a cure for the investor blues on Monday. Shares of the company rose more than 2% in price on an analyst's recommendation upgrade. AbbVie stock's
Why Coherus BioSciences Stock Soared Today
Shares of Coherus Biosciences (NASDAQ: CHRS) closed up 14% on Monday after the company announced the long-awaited approval of its drug, Loqtorzi, by the U.S. Food and Drug Administration (FDA).
In a
2 No-Brainer Dividend Stocks to Buy This Week
Dividend stocks can be consistent market-beaters. However, empirical research shows that the best dividend stocks tend to generate better-than-average returns because of their underlying value
Better Dividend Stock: AT&T vs. Verizon
Third-quarter earnings reports are in, and AT&T (NYSE: T) and Verizon (NYSE: VZ) soared on their respective results. For the telecom giants, their years-long declines could finally be over.
AT&T hit
This Stock Pays You 7% Just to Own It
Artificial intelligence (AI) has become all the rage over the past year. Investors are constantly looking to identify the next company that could emerge as a leader in generative AI, and current
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Healthcare companies are spending big on developing treatments for inflammatory bowel disease (IBD), which consists of either Crohn's disease or ulcerative colitis (UC), or both. The lure for IBD
Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?
When it comes to picking winning biotech companies, sometimes it pays to go with players who are at the cutting edge of their field. On Oct. 18, regulators at the Food and Drug Administration (FDA)
3 No-Brainer Stocks to Buy for Under $100 Right Now
Benjamin Franklin would probably be disappointed that the $100 bill that bears his likeness isn't worth what it used to be. However, there are actually plenty of great stocks to be found that you
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
Sometimes, the old financial adages are spot on. For example, it does take money to make money. And the expression that "time is money" is correct in many ways.
But it's also true that some
Why AbbVie Stock Fell Today
Shares of AbbVie (NYSE: ABBV) were down 5.4% as of 2:00 p.m. ET Friday, even after the pharmaceuticals giant announced slightly better-than-expected quarterly results and raised its full-year